10-Q · May 12, 2026
Damora Therapeutics, Inc. reported a significant increase in operating expenses for Q1 2026, with total operating expenses reaching $30.8 million, up 1085% from $2.6 million in Q1 2025. The net loss for the quarter was…
Earnings analysis · 10-Q
DMRA earnings analysis
Filed August 10, 2026 · Our reading of the company's report
The latest report
Damora remains a loss-making, preclinical biotechnology company with no product revenue disclosed and a net loss of $31.2 million for the quarter, up from $27.8 million in Q1 2026 and $3.4 million in the prior-year…
Read full summary
Damora remains a loss-making, preclinical biotechnology company with no product revenue disclosed and a net loss of $31.2 million for the quarter, up from $27.8 million in Q1 2026 and $3.4 million in the prior-year quarter. The key positive is a $540.5 million cash balance, which management expects to support operations into the second half of 2029, although additional financing will still be required. DMR-001 has entered Phase 1/1b development, but regulatory, clinical, manufacturing and financing risks remain substantial.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Substantial Cash Runway
Cash and cash equivalents were $540.5 million as of June 30, 2026. Management expects this balance to fund operations into the second half of 2029.
-
DMR-001 Enters Phase 1/1b
The company recently initiated its Phase 1/1b DMR-001 trial, with health-authority clearance received in the first country. It plans additional regulatory submissions to expand the trial globally in the second half of 2026.
-
Controls Rated Effective
Management reported no material legal matters or claims and stated that disclosure controls were effective at the reasonable assurance level as of June 30, 2026.
-
Board Adds Biotech Expertise
An additional director, Andrew Cheng, M.D., Ph.D., was appointed effective August 12, 2026, increasing the board size from 6 to 7 members.
What to watch
-
Losses Continue to Expand
Net loss increased to $31.2 million for the three months ended June 30, 2026, versus $3.4 million in the comparable 2025 period and $27.8 million reported for Q1 2026. Accumulated deficit reached $546.3 million as of June 30, 2026.
-
Future Financing Required
Despite $540.5 million of cash and cash equivalents, management states that additional capital will be required in the future and that failure to raise capital could raise substantial doubt about the company's ability to continue as a going concern.
-
Clinical and Safety Uncertainty
The company remains preclinical for most programs and has no products administered to humans or approved for commercial sale. DMR-001 is substantially important to the company's prospects, while the filing cites 4 discontinuations among 55 patients in a competitor's Phase 1 trial, including 1 due to a treatment-emergent adverse event.
-
Foreign Manufacturing Exposure
The company relies on foreign CROs and CMOs, including WuXi Biologics (Hong Kong), which was identified in connection with the BIOSECURE Act. The filing states that the act includes a grandfathering period lasting up to 5 years from the effective date of relevant regulatory revisions, creating potential supply, cost and timing risks.
-
Tariff and Supply-Chain Risk
The filing highlights potential 100% tariffs on imported branded or patented pharmaceuticals announced in September 2025, with uncertainty over whether clinical-trial active ingredients and bulk drug products would be covered. Such tariffs could increase trial-material costs and delay development.
-
Limited Addressable Market
The target population for DMR-001 is estimated at more than 42,000 patients in the United States with mutCALR proteins, but management acknowledges that patient-population estimates may be incorrect and that a smaller population could reduce potential revenue.
Management's outlook
No numeric revenue or EPS guidance was provided in the extracted 10-Q. Management stated that $540.5 million of cash and cash equivalents as of June 30, 2026 is expected to fund operations into the second half of 2029, and that additional capital will still be required in the future. The company also plans additional DMR-001 regulatory submissions in the second half of 2026.
Earlier filings 4
10-K · March 19, 2026
Damora Therapeutics (DMRA) repositioned as a preclinical hematology company after its November 2025 asset acquisition and is focused on a mutCALR-directed portfolio led by DMR-001. The company plans IND/CTA filings for…
10-Q · August 5, 2025
Galecto reported a materially narrower net loss for Q2 2025 of $3.4 million ($2.60 loss per share) versus $5.3 million ($4.92 loss per share) in Q2 2024, driven by lower R&D and G&A spend. Cash and total assets declined…
10-Q · November 1, 2024
Galecto reported materially lower operating losses versus prior year periods driven by sharply reduced R&D spend and completed restructuring. Cash and invested securities declined — cash and cash equivalents were $19.7M…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.